Filtered By:
Specialty: Cardiology
Drug: Norvasc
This page shows you your search results in order of date.
Order by Relevance | Date
Total 22 results found since Jan 2013.
Effect of Amlodipine in Stroke and Myocardial infarction: A Systematic Review and Meta-analysis
ConclusionIn the pooled analysis of data from 12 randomised controlled trials and one double-blinded cohort study measuring the effect of CCBs, we found that the CCB amlodipine reduced the risk of stroke and MI in hypertensive patients. Superior results for amlodipine were found in ten of the 13 studies included in this meta-analysis.
Source: Cardiology and Therapy - September 4, 2021 Category: Cardiology Source Type: research
Cardiovascular Benefits of Angiotensin Converting Enzyme Inhibition plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and with Resistant Hypertension.
CONCLUSIONS: Combination therapy adding a calcium channel blocker, rather than hydrochlorothiazide, to an angiotensin converting enzyme inhibitor was more effective in preventing composite cardiovascular events even in hypertensive patients achieving aggressive systolic blood pressure targets as well as in those with apparent resistant hypertension. Our findings add support that most patients, including those following contemporary clinical guidelines, will benefit from this combination.
TRIAL REGISTRATION: ClinicalTrials.gov, NCT00170950.
PMID: 33216879 [PubMed - as supplied by publisher]
Source: American Journal of Hypertension - November 20, 2020 Category: Cardiology Authors: Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber MA, Jamerson KA, ACCOMPLISH investigators Tags: Am J Hypertens Source Type: research
ASCOT: Amlodipine Cuts Stroke, Not Dementia Over Decades ASCOT: Amlodipine Cuts Stroke, Not Dementia Over Decades
Long-term follow up of the ASCOT trial comparing amlodipine- vs atenolol-based antihypertensive regimens shows reductions in stroke, but not dementia, with amlodipine over time.Medscape Medical News
Source: Medscape Cardiology Headlines - June 17, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news
Association of Blood Pressure Measurements with Peripheral Arterial Disease Events: A Reanalysis of the ALLHAT Data.
Conclusions -In this re-analysis of data from ALLHAT, we found a higher rate of lower extremity PAD events with higher and lower SBP and PP, and with lower DBP. Given the recent revised blood pressure guidelines advocating lower SBP targets for overall cardiovascular risk reduction, further refinement of optimal blood pressure targets specific to PAD is needed. Clinical Trial Registration -URL: www.clinicaltrials.gov Unique identifier: NCT00000542.
PMID: 29930023 [PubMed - as supplied by publisher]
Source: Circulation - June 21, 2018 Category: Cardiology Authors: Itoga NK, Tawfik DS, Lee CK, Maruyama S, Leeper NJ, Chang TI Tags: Circulation Source Type: research
Fixed ‐dose vs free‐dose combinations for the management of hypertension—An analysis of 81 958 patients
Fixed‐dose combinations (FDC) have been developed to reduce the pill burden for hypertensive patients. Data on fixed‐dose or free‐dose (freeDC) ramipril/amlodipine (R/A) or candesartan/amlodipine (C/A) combination treatment initiation were assessed. 71 463 patients were prescribed R/A and 10 495 C/A. For both R/A and C/A, FDC patients were younger (both P < .001) and less comorbid. Prior MI (OR: 0.61 and 0.60), prior stroke (OR: 0.68 and 0.70) and CHD (OR: 0.68 and 0.64) were negatively associated with FDC use, whereas hyperlipidemia was positively associated (OR: 1.26 and 1.19). Use of antihypertensive comedi...
Source: The Journal of Clinical Hypertension - February 19, 2018 Category: Cardiology Authors: Peter Bramlage, Stefanie Schmidt, Helen Sims Tags: ORIGINAL PAPER Source Type: research
The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications.
CONCLUSION: Decline in eGFR over 2 years is associated with increased risk of clinical outcomes beyond the effects of baseline eGFR. These risks were the same irrespective of the primary medication used to treat HTN.
PMID: 29360915 [PubMed - as supplied by publisher]
Source: American Journal of Hypertension - January 19, 2018 Category: Cardiology Authors: Barzilay JI, Davis BR, Pressel SL, Ghosh A, Rahman M, Einhorn PT, Cushman WC, Whelton PK, Wright JT Tags: Am J Hypertens Source Type: research
Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform
AbstractDespite the improvements in the management of hypertension during the last three decades, it continues to be one of the leading causes of cardiovascular morbidity and mortality worldwide. Effective and sustained reductions in blood pressure (BP) reduce the incidence of myocardial infarction, stroke, congestive heart failure and cardiovascular death. However, the proportion of patients who achieve the recommended BP goal (< 140/90 mmHg) is persistently low, worldwide. Poor adherence to therapy, complex therapeutic regimens, clinical inertia, drug-related adverse events and multiple risk factors or comorbiditie...
Source: High Blood Pressure and Cardiovascular Prevention - October 31, 2017 Category: Cardiology Source Type: research
Abstract P480: Effects Of Long And Intermediate Acting Dihydropyridine Calcium Channel Blockers In Hypertension: A Systematic Review And Aeta-analysis Of 18 Prospective, Actively Controlled, Randomized Clinical Trials Session Title: Antihypertensive Drugs and Pharmacology, Patient-Provider-Healthcare System Issues, and Pediatric and Adolescent Hypertension
Conclusions: This study suggests that Amlodipine offers greater protection against major complications of hypertension compared to intermediate acting dihydropyridine calcium channel blockers.
Source: Hypertension - September 14, 2017 Category: Cardiology Authors: Sandip Chaugai, Hisatomi Arima, Lhamo Yangchen Sherpa, Amir Sepehry Tags: Poster Abstract Presentations Source Type: research
Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control
AbstractRecent epidemiological surveys have demonstrated that effective and sustained blood pressure (BP) control is achieved in a relatively small proportion of treated hypertensive patients. Indeed, treatment of hypertension represents a key strategy for preventing coronary artery disease, stroke, congestive heart failure and cardiovascular death. Several interventions have been proposed by international guidelines for ameliorating hypertension management and control, mostly including integrated and multi-dimensional pharmacological and non-pharmacological strategies. In particular, numerous evidence demonstrated that a ...
Source: High Blood Pressure and Cardiovascular Prevention - June 12, 2017 Category: Cardiology Source Type: research
Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)Novelty and Significance Clinical Trials
Randomized trials of hypertension have seldom examined heterogeneity in response to treatments over time and the implications for cardiovascular outcomes. Understanding this heterogeneity, however, is a necessary step toward personalizing antihypertensive therapy. We applied trajectory-based modeling to data on 39 763 study participants of the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) to identify distinct patterns of systolic blood pressure (SBP) response to randomized medications during the first 6 months of the trial. Two trajectory patterns were identified: immediate responde...
Source: Hypertension - June 7, 2017 Category: Cardiology Authors: Sanket S. Dhruva, Chenxi Huang, Erica S. Spatz, Andreas C. Coppi, Frederick Warner, Shu-Xia Li, Haiqun Lin, Xiao Xu, Curt D. Furberg, Barry R. Davis, Sara L. Pressel, Ronald R. Coifman, Harlan M. Krumholz Tags: Cardiovascular Disease, Hypertension, Quality and Outcomes Original Articles Source Type: research
Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study.
CONCLUSIONS: Baseline Cornell voltage LVH is associated with increased CV morbidity and all-cause mortality in treated hypertensive patients independent of treatment modality and other CV risk factors.
CLINICAL TRIALS REGISTRATION: Trial Number NCT00000542.
PMID: 28430947 [PubMed - as supplied by publisher]
Source: American Journal of Hypertension - April 19, 2017 Category: Cardiology Authors: Bang CN, Soliman EZ, Simpson LM, Davis BR, Devereux RB, Okin PM, and for the ALLHAT Collaborative Research Group Tags: Am J Hypertens Source Type: research
Rationale for a Single-Pill Combination of Perindopril Arginine and Amlodipine Besylate
A systematic review identified 86 outcome-based clinical trials involving perindopril, amlodipine, or other antihypertensive drugs. In fixed-effects meta-analyses of 11 clinical trials (90,208 subjects), amlodipine was associated with a significant 24% increase in heart failure, but a significant decrease in death, cardiovascular death, stroke, coronary heart disease, and first major cardiovascular adverse event. In 5 clinical trials (52,565 subjects), perindopril was associated with a significant reduction in all six cardiovascular endpoints.
Source: Journal of the American Society of Hypertension - January 14, 2015 Category: Cardiology Authors: William J. Elliott Source Type: research
Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trial
Pulse pressure (PP) is an independent risk factor for cardiovascular (CV) disease and death but few studies have investigated the effect of antihypertensive treatments in relation to PP levels before treatment. The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial showed that the combination of benazepril+amlodipine (B+A) is superior to benazepril+hydrochlorothiazide (B+H) in reducing CV events. We aimed to investigate whether the treatment effects in the ACCOMPLISH trial were dependent on baseline PP. High‐risk hypertensive patients (n=11,499) wer...
Source: The Journal of Clinical Hypertension - December 22, 2014 Category: Cardiology Authors: Per H. Skoglund, Per Svensson, Joline Asp, Björn Dahlöf, Sverre E. Kjeldsen, Kenneth A. Jamerson, Michael A. Weber, Yan Jia, Dion H. Zappe, Jan Östergren, Tags: Original Paper Source Type: research
Critical Blood Pressure Threshold Dependence of Hypertensive Injury and Repair in a Malignant Nephrosclerosis Model Kidney
Most patients with essential hypertension do not exhibit substantial renal damage. Renal autoregulation by preventing glomerular transmission of systemic pressures has been postulated to mediate this resistance. Conversely, malignant nephrosclerosis (MN) has been postulated to develop when severe hypertension exceeds a critical ceiling. If the concept is valid, even modest blood pressure (BP) reductions to below this threshold regardless of antihypertensive class (1) should prevent MN and (2) lead to the healing of the already developed MN lesions. Both predicates were tested using BP radiotelemetry in the stroke-prone spo...
Source: Hypertension - September 10, 2014 Category: Cardiology Authors: Griffin, K. A., Polichnowski, A., Litbarg, N., Picken, M., Venkatachalam, M. A., Bidani, A. K. Tags: Animal models of human disease Kidney Source Type: research
Stroke Outcomes Among Participants Randomized To Chlorthalidone, Amlodipine Or Lisinopril In Allhat
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was a randomized, double-blind, practice-based, active-control, comparative effectiveness trial in 33,357 high-risk hypertensive participants.
Source: Journal of the American Society of Hypertension - August 19, 2014 Category: Cardiology Authors: José-Miguel Yamal, Suzanne Oparil, Barry R. Davis, Michael H. Alderman, David A. Calhoun, William C. Cushman, Herbert F. Fendley, Stanley S. Franklin, Gabriel B. Habib, Sara L. Pressel, Jeffrey L. Probstfield, Sithiporn Sastrasinh, ALLHAT Collaborative R Source Type: research
